LEXICON PHARMACEUTICALS, INC. Payments to Acquire Investments
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Payments to Acquire Investments of $163.22 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-08-06
- LEXICON PHARMACEUTICALS, INC. payments to acquire investments for the quarter ending 2026-06-30 was $57.26M, a 120.47% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. payments to acquire investments for the quarter ending 2026-03-31 was $105.96M, a 63.09% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. payments to acquire investments for the quarter ending 2025-12-31 was $22.17M, a 14.16% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. payments to acquire investments for the quarter ending 2025-09-30 was $26.73M, a 37.30% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. payments to acquire investments for fiscal 2025 was $139.84M, a 57.46% decline from fiscal 2024.
- LEXICON PHARMACEUTICALS, INC. payments to acquire investments for fiscal 2024 was $328.75M, a 47.19% increase from fiscal 2023.
- LEXICON PHARMACEUTICALS, INC. payments to acquire investments for fiscal 2023 was $223.34M, a 66.74% increase from fiscal 2022.
- LEXICON PHARMACEUTICALS, INC. payments to acquire investments for fiscal 2022 was $133.95M, a 290.97% increase from fiscal 2021.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $57.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $163.22M 10-Q · filed 2026-08-06 | $185.39M derived: sum of 3 quarters · filed 2026-08-06 | $212.12M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $105.96M 10-Q · filed 2026-05-07 | $128.13M derived: sum of 2 quarters · filed 2026-05-07 | $154.85M derived: sum of 3 quarters · filed 2026-05-07 | $180.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $22.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $48.90M derived: sum of 2 quarters · filed 2026-03-05 | $74.87M derived: sum of 3 quarters · filed 2026-08-06 | $139.84M 10-K · filed 2026-03-05 |
| 2025-09-30 | $26.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $52.70M derived: sum of 2 quarters · filed 2026-08-06 | $117.67M 10-Q · filed 2025-11-06 | $143.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $25.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $90.94M 10-Q · filed 2026-08-06 | $116.77M derived: sum of 3 quarters · filed 2026-08-06 | $159.39M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $64.97M 10-Q · filed 2026-05-07 | $90.80M derived: sum of 2 quarters · filed 2026-05-07 | $133.42M derived: sum of 3 quarters · filed 2026-05-07 | $210.49M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $25.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $68.45M derived: sum of 2 quarters · filed 2026-03-05 | $145.52M derived: sum of 3 quarters · filed 2026-03-05 | $328.75M 10-K · filed 2026-03-05 |
| 2024-09-30 | $42.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $119.70M derived: sum of 2 quarters · filed 2025-11-06 | $302.92M 10-Q · filed 2025-11-06 | $303.02M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | $77.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $260.30M 10-Q · filed 2025-08-06 | $260.40M derived: sum of 3 quarters · filed 2026-03-05 | $332.64M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | $183.22M 10-Q · filed 2025-05-14 | $183.33M derived: sum of 2 quarters · filed 2026-03-05 | $255.57M derived: sum of 3 quarters · filed 2026-03-05 | $377.70M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $102.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $72.34M derived: sum of 2 quarters · filed 2026-03-05 | $194.48M derived: sum of 3 quarters · filed 2026-03-05 | $223.34M 10-K · filed 2026-03-05 |
| 2023-09-30 | $72.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $194.38M derived: sum of 2 quarters · filed 2024-11-13 | $223.24M 10-Q · filed 2024-11-13 | $223.83M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-06-30 | $122.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $151.00M 10-Q · filed 2024-08-02 | $151.58M derived: sum of 3 quarters · filed 2025-03-07 | $244.78M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-03-31 | $28.86M 10-Q · filed 2024-05-02 | $29.45M derived: sum of 2 quarters · filed 2025-03-07 | $122.64M derived: sum of 3 quarters · filed 2025-03-07 | $145.00M derived: sum of 4 quarters · filed 2025-03-07 |
| 2022-12-31 | $586.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $93.78M derived: sum of 2 quarters · filed 2025-03-07 | $116.13M derived: sum of 3 quarters · filed 2025-03-07 | $133.95M 10-K · filed 2025-03-07 |
| 2022-09-30 | $93.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $115.55M derived: sum of 2 quarters · filed 2023-11-08 | $133.36M 10-Q · filed 2023-11-08 | $138.74M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-06-30 | $22.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $40.17M 10-Q · filed 2023-08-04 | $45.55M derived: sum of 3 quarters · filed 2024-03-25 | $50.06M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-03-31 | $17.82M 10-Q · filed 2023-05-04 | $23.20M derived: sum of 2 quarters · filed 2024-03-25 | $27.70M derived: sum of 3 quarters · filed 2024-03-25 | $30.39M derived: sum of 4 quarters · filed 2024-03-25 |
| 2021-12-31 | $5.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $9.89M derived: sum of 2 quarters · filed 2024-03-25 | $12.57M derived: sum of 3 quarters · filed 2024-03-25 | $34.26M 10-K · filed 2024-03-25 |
| 2021-09-30 | $4.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $7.19M derived: sum of 2 quarters · filed 2022-11-09 | $28.88M 10-Q · filed 2022-11-09 | $34.24M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-06-30 | $2.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $24.37M 10-Q · filed 2022-08-03 | $29.73M derived: sum of 3 quarters · filed 2023-03-03 | $45.78M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-03-31 | $21.69M 10-Q · filed 2022-05-05 | $27.04M derived: sum of 2 quarters · filed 2023-03-03 | $43.09M derived: sum of 3 quarters · filed 2023-03-03 | $47.02M derived: sum of 4 quarters · filed 2023-03-03 |
| 2020-12-31 | $5.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $21.41M derived: sum of 2 quarters · filed 2023-03-03 | $25.33M derived: sum of 3 quarters · filed 2023-03-03 | $58.55M 10-K · filed 2023-03-03 |
| 2020-09-30 | $16.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $19.98M derived: sum of 2 quarters · filed 2021-11-09 | $53.20M 10-Q · filed 2021-11-09 | $198.59M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-06-30 | $3.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $37.15M 10-Q · filed 2021-08-06 | $182.55M derived: sum of 3 quarters · filed 2022-03-10 | $252.83M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-03-31 | $33.22M 10-Q · filed 2021-05-06 | $178.62M derived: sum of 2 quarters · filed 2022-03-10 | $248.90M derived: sum of 3 quarters · filed 2022-03-10 | $268.35M derived: sum of 4 quarters · filed 2022-03-10 |
| 2019-12-31 | $145.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $215.68M derived: sum of 2 quarters · filed 2022-03-10 | $235.13M derived: sum of 3 quarters · filed 2022-03-10 | $322.38M 10-K · filed 2022-03-10 |
| 2019-09-30 | $70.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $89.73M derived: sum of 2 quarters · filed 2020-10-30 | $176.99M 10-Q · filed 2020-10-30 | $212.50M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-06-30 | $19.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | $106.71M 10-Q · filed 2020-07-29 | $142.22M derived: sum of 3 quarters · filed 2021-03-12 | $177.06M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-03-31 | $87.26M 10-Q · filed 2020-04-27 | $122.77M derived: sum of 2 quarters · filed 2021-03-12 | $157.60M derived: sum of 3 quarters · filed 2021-03-12 | $160.35M derived: sum of 4 quarters · filed 2021-03-12 |
| 2018-12-31 | $35.51M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $70.35M derived: sum of 2 quarters · filed 2021-03-12 | $73.09M derived: sum of 3 quarters · filed 2021-03-12 | $119.99M 10-K · filed 2021-03-12 |
| 2018-09-30 | $34.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $37.58M derived: sum of 2 quarters · filed 2019-11-07 | $84.47M 10-Q · filed 2019-11-07 | $293.11M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $2.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $49.64M 10-Q · filed 2019-08-01 | $258.27M derived: sum of 3 quarters · filed 2020-03-12 | $257.52M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $46.89M 10-Q · filed 2019-05-01 | $255.53M derived: sum of 2 quarters · filed 2020-03-12 | $254.78M derived: sum of 3 quarters · filed 2020-03-12 | $253.86M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | $208.64M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $207.88M derived: sum of 2 quarters · filed 2020-03-12 | $206.97M derived: sum of 3 quarters · filed 2020-03-12 | $267.87M 10-K · filed 2020-03-12 |
| 2017-09-30 | -$752.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | -$1.67M derived: sum of 2 quarters · filed 2018-11-01 | $59.24M 10-Q · filed 2018-11-01 | $148.26M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-06-30 | -$916.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-30 | $59.99M 10-Q · filed 2018-07-30 | $149.01M derived: sum of 3 quarters · filed 2019-03-15 | $266.23M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-03-31 | $60.91M 10-Q · filed 2018-05-03 | $149.93M derived: sum of 2 quarters · filed 2019-03-15 | $267.14M derived: sum of 3 quarters · filed 2019-03-15 | $277.59M derived: sum of 4 quarters · filed 2019-03-15 |
| 2016-12-31 | $89.02M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $206.24M derived: sum of 2 quarters · filed 2019-03-15 | $216.69M derived: sum of 3 quarters · filed 2019-03-15 | $425.67M 10-K · filed 2019-03-15 |
| 2016-09-30 | $117.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $127.66M derived: sum of 2 quarters · filed 2017-11-08 | $336.65M 10-Q · filed 2017-11-08 | $580.54M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $10.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-01 | $219.44M 10-Q · filed 2017-08-01 | $463.33M derived: sum of 3 quarters · filed 2018-03-01 | $475.38M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $208.99M 10-Q · filed 2017-05-04 | $452.88M derived: sum of 2 quarters · filed 2018-03-01 | $464.93M derived: sum of 3 quarters · filed 2018-03-01 | $464.45M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $243.89M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $255.94M derived: sum of 2 quarters · filed 2018-03-01 | $255.47M derived: sum of 3 quarters · filed 2018-03-01 | $326.45M 10-K · filed 2018-03-01 |
| 2015-09-30 | $12.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $11.58M derived: sum of 2 quarters · filed 2016-11-07 | $82.55M 10-Q · filed 2016-11-07 | $283.86M derived: sum of 4 quarters · filed 2017-03-06 |
| 2015-06-30 | -$473.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $70.50M 10-Q · filed 2016-08-04 | $271.81M derived: sum of 3 quarters · filed 2017-03-06 | $271.81M derived: sum of 4 quarters · filed 2017-03-06 |
| 2015-03-31 | $70.98M 10-Q · filed 2016-05-05 | $272.28M derived: sum of 2 quarters · filed 2017-03-06 | $272.28M derived: sum of 3 quarters · filed 2017-03-06 | $272.28M derived: sum of 4 quarters · filed 2017-03-06 |
| 2014-12-31 | $201.30M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | $201.30M derived: sum of 2 quarters · filed 2017-03-06 | $201.30M derived: sum of 3 quarters · filed 2017-03-06 | $221.95M 10-K · filed 2017-03-06 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $0.00 derived: sum of 2 quarters · filed 2015-11-09 | $20.65M 10-Q · filed 2015-11-09 | $51.19M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $20.65M 10-Q · filed 2015-08-07 | $51.19M derived: sum of 3 quarters · filed 2016-03-11 | $51.19M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-03-31 | $20.65M 10-Q · filed 2015-05-05 | $51.19M derived: sum of 2 quarters · filed 2016-03-11 | $51.19M derived: sum of 3 quarters · filed 2016-03-11 | $51.19M derived: sum of 4 quarters · filed 2016-03-11 |
| 2013-12-31 | $30.54M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $30.54M derived: sum of 2 quarters · filed 2016-03-11 | $30.54M derived: sum of 3 quarters · filed 2016-03-11 | $111.49M 10-K · filed 2016-03-11 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $0.00 derived: sum of 2 quarters · filed 2014-11-06 | $80.95M 10-Q · filed 2014-11-06 | $162.43M derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $80.95M 10-Q · filed 2014-08-07 | $162.43M derived: sum of 3 quarters · filed 2015-03-12 | $162.43M derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-03-31 | $80.95M 10-Q · filed 2014-05-08 | $162.43M derived: sum of 2 quarters · filed 2015-03-12 | $162.43M derived: sum of 3 quarters · filed 2015-03-12 | $162.43M derived: sum of 4 quarters · filed 2015-03-12 |
| 2012-12-31 | $81.47M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $81.47M derived: sum of 2 quarters · filed 2015-03-12 | $81.47M derived: sum of 3 quarters · filed 2015-03-12 | $233.25M 10-K · filed 2015-03-12 |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $0.00 derived: sum of 2 quarters · filed 2013-11-12 | $151.78M 10-Q · filed 2013-11-12 | $177.24M derived: sum of 4 quarters · filed 2014-03-07 |
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01 | $151.78M 10-Q · filed 2013-08-01 | $177.24M derived: sum of 3 quarters · filed 2014-03-07 | $195.74M derived: sum of 4 quarters · filed 2014-03-07 |
| 2012-03-31 | $151.78M 10-Q · filed 2013-05-10 | $177.24M derived: sum of 2 quarters · filed 2014-03-07 | $195.74M derived: sum of 3 quarters · filed 2014-03-07 | $225.97M derived: sum of 4 quarters · filed 2014-03-07 |
| 2011-12-31 | $25.47M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-07 | $43.97M derived: sum of 2 quarters · filed 2014-03-07 | $74.20M derived: sum of 3 quarters · filed 2014-03-07 | $108.09M 10-K · filed 2014-03-07 |
| 2011-09-30 | $18.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $48.73M derived: sum of 2 quarters · filed 2012-11-07 | $82.63M 10-Q · filed 2012-11-07 | $232.48M derived: sum of 4 quarters · filed 2013-03-11 |
| 2011-06-30 | $30.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02 | $64.13M 10-Q · filed 2012-08-02 | $213.98M derived: sum of 3 quarters · filed 2013-03-11 | $219.98M derived: sum of 4 quarters · filed 2013-03-11 |
| 2011-03-31 | $33.90M 10-Q · filed 2012-05-03 | $183.75M derived: sum of 2 quarters · filed 2013-03-11 | $189.75M derived: sum of 3 quarters · filed 2013-03-11 | |
| 2010-12-31 | $149.86M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-11 | $155.86M derived: sum of 2 quarters · filed 2013-03-11 | $155.86M 10-K · filed 2013-03-11 | |
| 2010-09-30 | $6.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-01 | $6.00M 10-Q · filed 2011-11-01 | ||
| 2010-06-30 | $0.00 10-Q · filed 2011-08-09 | |||
| 2009-12-31 | $59.95M 10-K · filed 2012-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |